<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02184806</url>
  </required_header>
  <id_info>
    <org_study_id>P080802</org_study_id>
    <nct_id>NCT02184806</nct_id>
  </id_info>
  <brief_title>Autograft of Human Ovarian Tissue : Efficiency and Safety</brief_title>
  <acronym>CAROLéLISA</acronym>
  <official_title>Autograft of Human Ovarian Tissue: Efficiency and Safety Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agence de La Biomédecine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ovarian tissue cryopreservation is a new technique for female fertility preservation. One way&#xD;
      to restore fertility is autotransplantation of ovarian tissue.&#xD;
&#xD;
      The principal purpose of this study will be to evaluate the efficiency and safety of this&#xD;
      procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian tissue cryopreservation is a new technique for female fertility preservation before&#xD;
      gonadotoxic treatments. The first ovarian tissue cryopreservations were performed 10 years&#xD;
      ago. There are two main methods to use frozen ovarian cortex: autograft of ovarian fragments&#xD;
      and in vitro follicular growth. At the present time, none mature oocytes were obtained after&#xD;
      culture. Since 2000, around twenty publications stating autografts of ovarian cortex reported&#xD;
      8 pregnancy and 6 life birth of healthy babies.&#xD;
&#xD;
      Since 1998 until 2008, in the unit of reproduction biology of pitie-salpetriere hospital in&#xD;
      Paris, France, 330 patients have had an ovarian tissue cryopreservation for fertility&#xD;
      preservation before gonadotoxic treatment. Among them, at the present time, 180 have a&#xD;
      procreative age and in consequence, could ask for the use of their ovarian cortex.&#xD;
&#xD;
      The general aim of this protocol will be to propose to women wishing to have a baby, an&#xD;
      ovarian tissue transplantation if the patients have an premature ovarian failure.&#xD;
&#xD;
      The principal aim of this study will be to evaluate the efficiency and the safety of ovarian&#xD;
      transplantation.&#xD;
&#xD;
      Before grafting, the absence of contra- indication will be check. An informed consent will be&#xD;
      signed by the patient. Autograft of ovarian cortex will be performed either in orthotopic or&#xD;
      in heterotopic localization according to the pathology and a possible contra-indication to&#xD;
      orthotopic position.&#xD;
&#xD;
      After graft, each month hormonal assessment, ovarian echography and, after 3 months, an MRI,&#xD;
      will be performed.&#xD;
&#xD;
      Assisted Reproductive Technologies (ART) will be performed in case of heterotopic graft and&#xD;
      if necessary in case of orthotopic graft.&#xD;
&#xD;
      The efficiency of ovarian tissue autograft will be appreciated by the delay before the&#xD;
      recovery of the ovarian function, the oocyte and embryos qualities in case of ART.&#xD;
&#xD;
      Finally, the number of pregnancies and live births will be also appreciated as well as a&#xD;
      possible recurrence of the pathology.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biological (FSH, LH, E2 and AMH) changes from graft until the revovery of ovarian function</measure>
    <time_frame>every month after graft, up to 18 months</time_frame>
    <description>FSH, LH, E2 and AMH follow up every month after graft until the recovery of ovarian function, up to 18 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological (ultrasonography and MRI) changes in ovarian imaging from graft until the revovery of ovarian function</measure>
    <time_frame>every month after graft, up to 18 months</time_frame>
    <description>Radiological (only ultrasonography the first 3 months and after ultrasonography and MRI) follow up every month after graft until the recovery of ovarian function, up to 18 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft vascularization</measure>
    <time_frame>every month up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of the pathology</measure>
    <time_frame>every month up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delay and quality of the ovarian function recovery between ortho and heterotopic graft</measure>
    <time_frame>after ovarian function recovery, up to 18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ovarian fragments necessary for ovarian function recovery</measure>
    <time_frame>up to 18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Ovarian Tissue Transplantation</condition>
  <arm_group>
    <arm_group_label>1- orthotopic graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2- heterotopic graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>orthotopic graft</intervention_name>
    <description>(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or</description>
    <arm_group_label>1- orthotopic graft</arm_group_label>
    <other_name>ovarian tissue autotransplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>heterotopic graft</intervention_name>
    <description>put under the skin&#xD;
the ovarian fragments can be put under the skin of the abdomen</description>
    <arm_group_label>2- heterotopic graft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  adult women (age ≥ 18 years old) who stored ovarian fragments before gonadotoxic&#xD;
             treatments&#xD;
&#xD;
          -  Women who desire to conceive&#xD;
&#xD;
          -  Married women or in stable couple&#xD;
&#xD;
          -  Cured women or in remission&#xD;
&#xD;
          -  Women suffering of Premature ovarian failure&#xD;
&#xD;
          -  Consenting women&#xD;
&#xD;
          -  women with health insurance&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  age &lt; 18 years&#xD;
&#xD;
          -  women with normal ovarian function&#xD;
&#xD;
          -  women with a disease at high risk for ovarian metastasis&#xD;
&#xD;
          -  women with contraindication for surgery&#xD;
&#xD;
          -  women with contraindication for pregnancy&#xD;
&#xD;
          -  not cured women or not in remission&#xD;
&#xD;
          -  women without health insurance&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poirot Catherine, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Poirot Catherine, MD, PhD</last_name>
    <phone>+33 1 56 01 78 00</phone>
    <email>Catherine.poirot@tnn.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Tenon, service de Biologie de la reproduction</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Poirot Catherine, MD, PhD</last_name>
      <phone>+33 1 56 01 78 00</phone>
      <email>Catherine.poirot@tnn.aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>June 13, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ovarian tissue transplantation</keyword>
  <keyword>Cryopreserved ovarian tissue</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

